3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
SCLC
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
High Grade Serous Carcinoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Malignancies
1
Adenocarcinoma
1
Interventions
Rituximab
187
Cyclophosphamide
174
Etoposide
94
Peripheral Blood Stem Cell Transplantation
90
Vincristine
89
Prednisone
80
Doxorubicin
79
Filgrastim
75
fludarabine phosphate
60
Radiotherapy
56
Mycophenolic Acid
41
Melphalan
41
Cytarabine
41
Busulfan
40
Cyclosporine
39
Methotrexate
37
Whole-Body Irradiation
36
Tacrolimus
35
Carmustine
34
Ifosfamide
28
Lenalidomide
27
Granulocyte Colony-Stimulating Factor
27
Antilymphocyte Serum
27
Gemcitabine
25
Carboplatin
25
Methylprednisolone
24
ibritumomab tiuxetan
23
Bortezomib
22
Dexamethasone
21
ibrutinib
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, Large B-Cell, Diffuse
×
ceralasertib
×
Clear all
NCT03527147
2022-08-15
PRISM
Acerta Pharma BV
Phase 1
Completed
30 enrolled